Takeda Pharmaceutical (NYSE:TAK) Upgraded by Sanford C. Bernstein to Outperform Rating

Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a market perform rating to an outperform rating in a research note released on Wednesday morning, MarketBeat reports.

A number of other research firms also recently issued reports on TAK. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen downgraded Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 21st. Morgan Stanley began coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

TAK opened at $18.67 on Wednesday. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. The business’s fifty day simple moving average is $18.17 and its 200-day simple moving average is $15.95. The company has a market capitalization of $59.43 billion, a price-to-earnings ratio of 77.81 and a beta of -0.01.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.The firm had revenue of $7.60 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. On average, equities research analysts anticipate that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in TAK. Arrowstreet Capital Limited Partnership boosted its position in Takeda Pharmaceutical by 100.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after purchasing an additional 2,854,069 shares in the last quarter. UBS Group AG boosted its position in Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares in the last quarter. Qube Research & Technologies Ltd boosted its position in Takeda Pharmaceutical by 407.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after purchasing an additional 1,426,184 shares in the last quarter. Van ECK Associates Corp boosted its position in Takeda Pharmaceutical by 98.4% during the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after purchasing an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its position in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after purchasing an additional 880,289 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.